The structure and gender characteristics of progressive pulmonary fibrosis according to retrospective research
https://doi.org/10.18093/0869-0189-2025-35-4-476-481
Abstract
Progressive pulmonary fibrosis (PLF) is a group of chronic interstitial lung diseases (ILD) that share common clinical, functional and radiological characteristics and have unfavorable prognosis.
The aim was to study the structure and course of PLF in patients with chronic ILD.
Methods. A retrospective analysis of 463 medical records of patients with chronic ILD aged 18 to 80 years was carried out for the period from January 2020 to December 2023. PLF was diagnosed based on the criteria of the American Thoracic Society (2022). Statistical data processing was carried out using the Statistica 10.0 program.
Results. Signs of PLF were detected in patients with idiopathic pulmonary fibrosis (ILF) in 91.1% of cases, in patients with ILD associated with systemic scleroderma (SSD) – in 71.4% of cases; in patients with hypersensitive pneumonitis (HP), nonspecific interstitial pneumonia (NSIP) and undifferentiated ILD – in 47.5%, 44.4%, and 31.1% of cases, respectively. The progression of pulmonary fibrosis in ILD associated with rheumatoid arthritis (RA) was 16.6%, in sarcoidosis – 2.5%. PLF was statistically significantly more often recorded in men with chronic HP (60% in men vs 40.5% in women; χ2 = 3.4; p = 0.02); and significantly more often in women with unclassified ILD (39% in women vs 24.5% in men; χ2 = 4.2; p = 0.033). Regardless of gender, patients with PLF were older than patients with ILD without signs of PLF (63.1 ± 8.7 years vs 53.8 ± 17.2 years; p = 0.007)
Conclusion. Signs of PLF were detected in 32.6% of patients with ILD. The highest incidence of PLF was recorded in the group with ILF and HP, the lowest in lung sarcoidosis. Regardless of gender, patients with ILD and PLF were older than patients without signs of PLF.
About the Authors
E. V. Bolotova
Federal State Budgetary Educational Institution of Higher Education “Kuban State Medical University” of the Ministry of Health of the Russian Federation
Russian Federation
Russian Federation
Elena V. Bolotova, Doctor of Medicine, Associate Professor, Professor, Depart ment of Therapy No.1, Faculty of Advanced Training and Postgraduate Training of Specialists
Yu. G. Yurkova
Federal State Budgetary Educational Institution of Higher Education “Kuban State Medical University” of the Ministry of Health of the Russian Federation;
Federal Budgetary Healthcare Institution “Research Institute – Regional Hospital No.1. Named after S.V.Ochapovskiy”
Russian Federation
Russian Federation
Yulia G. Yurkova, Postgraduate Student, Department of Pulmonology, Fa culty of Advanced Training and Postgraduate Training of Specialists, Kuban State Medical University; Pul monologist, Consultative and Diagnostic Center, Research Institute – Regional Hospital No.1 named after S.V.Ochapovskiy
L. V. Shul’zhenko
Federal State Budgetary Educational Institution of Higher Education “Kuban State Medical University” of the Ministry of Health of the Russian Federation;
Federal Budgetary Healthcare Institution “Research Institute – Regional Hospital No.1. Named after S.V.Ochapovskiy”
Russian Federation
Russian Federation
Larisa V. Shul’zhenko, Doctor of Medicine, Professor, Head of Department of Pulmonology, Faculty of Postgraduate Physician Training, Kuban State Medical University; Head of the Department of Pulmonology, Research Institute – Regional Hospital No.1 named after S.V.Ochapovskiy
References
1. Avdeev S.N., Aisanov Z.R., Belevskiy A.S. et al. [Federal clinical guidelines on diagnosis and treatment of idiopathic pulmonary fibrosis]. Pul'monologiya. 2022; 32 (3): 473–495. DOI: 10.18093/0869-0189-2022-32-3-473-495 (in Russian).
2. Kuzubova N.A., Titova O.N., Skliarova D.V. [Interstital lung diseases with progressive pulmonary fibrosis: phatogenetic features and approaches to therapy]. Meditsinskiy sovet. 2020; (17): 99–106. DOI: 10.21518/2079-701X-2020-17-99-106 (in Russian).
3. Cottin V., Wollin L., Fischer A. et al. Fibrosing interstitial lung diseases: knowns and unknowns. Eur. Respir. Rev. 2019; 28 (151): 180100. DOI: 10.1183/16000617.0100-2018.
4. George P.M., Spagnolo P., Kreuter M. et al. Progressive fibrosing interstitial lung disease: clinical uncertainties, consensus recommendations, and research priorities. Lancet Respir. Med. 2020; 8 (9): 925–934. DOI: 10.1016/S2213-2600(20)30355-6.
5. Rajan S.K., Cottin V., Dhar R. et al. Progressive pulmonary fibrosis: an expert group consensus statement. Eur. Respir. J. 2023; 61 (3): 2103187. DOI: 10.1183/13993003.03187-2021.
6. Bowman W.S., Newton C.A., Linderholm A.L. et al. Proteomic biomarkers of progressive fibrosing interstitial lung disease: a multicentre cohort analysis. Lancet Respir. Med. 2022; 10 (6): 593–602. DOI: 10.1016/S2213-2600(21)00503-8.
7. Olson A.L., Patnaik P., Hartmann N. et al. Prevalence and incidence of chronic fibrosing interstitial lung diseases with a progressive phenotype in the United States estimated in a large claims database analysis. Adv. Ther. 2021; 38 (7): 4100–4114. DOI: 10.1007/s12325-021-01786-8.
8. Olson A., Hartmann N., Patnaik P. et al. Estimation of the prevalence of progressive fibrosing interstitial lung diseases: systematic literature review and data from a physician survey. Adv. Ther. 2021; 38 (2): 854–867. DOI: 10.1007/s12325-020-01578-6.
9. Nashatyreva M.S., Trofimenko I.N., Chernyak B.A. [Chronic fibrosing interstitial lung diseases according to the register of Irkutsk (Russia)]. Pul’monologiya. 2022; 32 (2): 199–207. DOI: 10.18093/0869-0189-2022-32-2-199-207 (in Russian).
10. Nashatyreva M.S., Trofimenko I.N., Chernyak B.A., Avdeev S.N. Pulmonary fibrosis and progressive pulmonary fibrosis in a prospective registry of interstitial lung diseases in Eastern Siberia. Life (Basel). 2023; 13 (1): 212. DOI: 10.3390/life13010212.
11. Faverio P., Piluso M., De Giacomi F. et al. Progressive fibrosing interstitial lung diseases: prevalence and characterization in two Italian referral centers. Respiration. 2020; 99 (10): 838–845. DOI: 10.1159/000509556.
12. Flaherty K.R., Wells A.U., Cottin V. et al. Nintedanib in progressive fibrosing interstitial lung diseases. N. Engl. J. Med. 2019; 381 (18): 1718–1727. DOI: 10.1056/NEJMoa1908681.
13. Hambly N., Farooqi M.M., Dvorkin-Gheva A. et al. Prevalence and characteristics of progressive fibrosing interstitial lung disease in a prospective registry. Eur. Respir. J. 2022; 60 (4): 2102571. DOI: 10.1183/13993003.02571-2021.
14. Morrisroe K., Hansen D., Stevens W. et al. Progressive pulmonary fibrosis and its impact on survival in systemic sclerosis-related interstitial lung disease. Rheumatology (Oxford). 2024; 63 (7): 1874–1881. DOI: 10.1093/rheumatology/kead491.
15. Perelas A., Silver R.M., Arrossi A.V., Highland K.B. Systemic sclerosis-associated interstitial lung disease. Lancet Respir. Med. 2020; 8 (3): 304–320. DOI: 10.1016/S2213-2600(19)30480–30481.
16. Denis A., Henket M., Ernst M. et al. Progressive fibrosing interstitial lung disease in rheumatoid arthritis: a retrospective study. Front. Med. (Lausanne). 2022; 9: 1024298. DOI: 10.3389/fmed.2022.1024298.
17. Gupta R., Kim J.S., Baughman R.P. An expert overview of pulmonary fibrosis in sarcoidosis. Expert Rev. Respir. Med. 2023; 17 (2): 119–130. DOI: 10.1080/17476348.2023.2183193.
18. Nunes H., Brillet P.Y., Bernaudin J.F. et al. Fibrotic pulmonary sarcoidosis. Clin. Chest Med. 2024; 45 (1): 199–212. DOI: 10.1016/j.ccm.2023.08.011.
Review
For citations:
Bolotova E.V., Yurkova Yu.G., Shul’zhenko L.V. The structure and gender characteristics of progressive pulmonary fibrosis according to retrospective research. PULMONOLOGIYA. 2025;35(4):476-481. (In Russ.) https://doi.org/10.18093/0869-0189-2025-35-4-476-481
Views:
13
Email this article 